Creating CAR-T Cells Using Current Alzheimer’s Antibodies
Researchers engineered CD4+ CAR‑T cells using aducanumab and lecanemab-derived CARs to target amyloid‑beta plaques; the lecanemab-derived CAR (Lec28z) showed greater reactivity and, when delivered transiently as mRNA in Alzheimer’s model mice, reduced amyloid and microglial activation across the brain, though bulk brain amyloidosis and behavioral effects were not assessed and persistent T cell activation raises safety concerns requiring further preclinical and human trials.
Why it mattersLecanemab-derived CAR-T using transient mRNA reduced plaques in mice, prompting developers to prioritize transient dosing in trials.